Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial

Abstract Triple-negative breast cancer (TNBC) remains a challenge for clinicians due to its aggressive behavior and scarcity of effective treatment. Interleukin 6 (IL-6) is well known to contribute to poor therapeutic gain, tumor relapse, and aggressive tumor growth. Here, we have explored targeting...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Taher Al-Tweigeri, Asma Tulbah, Syed Akhtar, Meshari Alzahrani, Saleh Najjar, Tusnem El Hassan, Noura N. Alraouji, Kauser Suleman, Adher AlSayed, Abdelilah Aboussekhra
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2026-02-01
coleção:	Scientific Reports
Assuntos:	Tocilizumab Triple-negative breast cancer Interleukin-6 Clinical trial
Acesso em linha:	https://doi.org/10.1038/s41598-026-38465-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!